Biotech Values

[ghmm]

I didn't expect a lot of detail but thought GSK may do a separate PR (I believe they did about a year ago when the Promacta trial was halted in chronic liver disease).

I noticed GSK breaking out Emerging Market sales this quarter I don't recall them doing that before (for any of their therapies).

Sales are finally showing some meaningful increases the last 4 consecutive quarters are (28MM, 19MM, 16MM, 11MM). I have figures by territory but i-hub doesn't give a good way to post tables.